论文部分内容阅读
我们实验观察到脾LAK细胞与外周血LAK一样,具有良好的增殖速度,其杀伤活性维持时间较长(22天),表型标记为OKT3+OKT4-OKT8+.异体脾LAK细胞与自体LAK细胞共同温育16小时后,用~(125)I-UdR释放法证实在较低效靶比(≤10∶1)时二者无明显的相互杀伤效应。将S_(180)肉瘤在C57BL小鼠上复制成癌性腹水后,用杂种鼠脾LAK和同系鼠脾LAK同时进行治疗,结果表明二者无差异(P>0.05)。结合文献报道,作者认为异体脾LAK细胞在肿瘤的过继免疫治疗中有一定的安全性和有效性。
Our experiments showed that LAK cells in the spleen have the same proliferation rate as the peripheral blood LAK cells, and their killing activity is maintained for a long time (22 days) and the phenotypic markers are OKT3 + OKT4-OKT8 +. Allogeneic spleen LAK cells are associated with autologous LAK cells After 16 hours of incubation, ~ (125) I-UdR release demonstrated no significant mutual killing at the lower target ratios (≤ 10: 1). After S 180 sarcoma was replicated into cancerous ascites in C57BL mice, splenic LAK and splenic LAK of the same strain were treated simultaneously. The results showed that there was no difference between the two groups (P> 0.05). Combined with the literature, the authors believe that allogeneic spleen LAK cells in the adoptive immunotherapy of the tumor has a certain safety and effectiveness.